Pancreatic Polypeptide in Parkinson’s Disease: A Potential Marker of Parasympathetic Denervation
- 1 November 2017
- journal article
- research article
- Published by IOS Press in Journal of Parkinson's Disease
- Vol. 7 (4), 645-652
- https://doi.org/10.3233/jpd-171189
Abstract
Background and objectives: Parkinson’s disease (PD) patients experience several non-motor symptoms from the gastrointestinal tract that may partly be caused by parasympathetic deficiency. The pancreas is densely innervated by the vagus nerve, which mThis publication has 39 references indexed in Scilit:
- Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplastyActa Endocrinologica, 2013
- Shared dysregulated pathways lead to Parkinson's disease and diabetesTrends in Molecular Medicine, 2013
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disordersActa Neuropathologica, 2010
- Cephalic phase pancreatic polypeptide responses to liquid and solid stimuli in humansPhysiology & Behavior, 2010
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009
- Pancreatic polypeptide response to insulin induced hypoglycaemia in Parkinsonʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 1999
- Evidence for dopaminergic modulation of pancreatic polypeptide secretion in manLife Sciences, 1982
- Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part I-Effect of vagotomy on response to oral glucose.BMJ, 1975
- ParkinsonismNeurology, 1967